Published February 24, 2020
| Version v1
Dataset
Open
mTOR-iMCD-Blood_Article_Data_Repository
Description
This permanent Zenodo entry corresponds to the original data used for the manuscript: "Increased mTOR activation in idiopathic multicentric Castleman disease" accepted for publication by Blood.
Original data for Figure 5 (proteomics) of the manuscript is available upon reasonable request to the corresponding author of the article.
Files
Figure1_pS6_122017_Sentinels.csv
Files
(17.6 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:285586584544af8f0970848a0fc39bfb
|
509 Bytes | Preview Download |
|
md5:0464183887bd13a084ee32695382eb3e
|
971 Bytes | Preview Download |
|
md5:dac6d82f192a76dc63f2c4545d078db6
|
441 Bytes | Preview Download |
|
md5:1a71a03c719444983e92d641d811810b
|
439 Bytes | Preview Download |
|
md5:de8816b129f99f4b72f69250743a9570
|
252 Bytes | Preview Download |
|
md5:62b7ff7e1812f970071e1316bcbbc5a5
|
620 Bytes | Preview Download |
|
md5:786a5438b73d7bfa6d787079fcf1be26
|
599 Bytes | Preview Download |
|
md5:b52ab9b6ed54d74c6a4ee6e75368aa88
|
526 Bytes | Preview Download |
|
md5:78f49695875363d2542f4df007580260
|
517 Bytes | Preview Download |
|
md5:b81d2e7caf5fe197c3e75e0739a7d9b9
|
974 Bytes | Preview Download |
|
md5:1d616e9451a40ee436f54d99c065fbe0
|
688 Bytes | Preview Download |
|
md5:71e6c809ad71a64dc9ba92cff10a3317
|
770 Bytes | Preview Download |
|
md5:fdf25fb8a531f58d4690f3df63c735d6
|
1.0 kB | Preview Download |
|
md5:a9457cc854d62da34c6286d798245784
|
1.7 kB | Preview Download |
|
md5:3bbddc1d0d0a301e721cddd1651f1ec4
|
721 Bytes | Preview Download |
|
md5:7e39620a757cd83da86e2d1ff4328feb
|
717 Bytes | Preview Download |
|
md5:40254f9ebb18836873bfa6e75fc275e0
|
180 Bytes | Preview Download |
|
md5:f2ffb98a13d46e9fb36605cbad11a102
|
6.0 kB | Preview Download |
Additional details
References
- Fajgenbaum, David C., et al. "Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6 blockade–refractory idiopathic multicentric Castleman disease." The Journal of clinical investigation 129.10 (2019): 4451-4463.
- Arenas, Daniel, et al. "Increased mTOR activation in idiopathic multicentric Castleman disease." Clinical Lymphoma Myeloma and Leukemia 19.10 (2019): e306.
- Fajgenbaum, David C., et al. "International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease." Blood, The Journal of the American Society of Hematology 129.12 (2017): 1646-1657.